First Trust NYSE Arca Biotechnology Index Fund (FBT)
| Assets | $1.12B |
| Expense Ratio | 0.56% |
| PE Ratio | 17.05 |
| Shares Out | 7.60M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -8.09% |
| Volume | 31,690 |
| Open | 144.63 |
| Previous Close | 145.05 |
| Day's Range | 144.80 - 146.43 |
| 52-Week Low | 130.27 |
| 52-Week High | 161.41 |
| Beta | n/a |
| Holdings | 31 |
| Inception Date | Jun 19, 2006 |
About FBT
Fund Home PageThe First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is issued by First Trust.
Top 10 Holdings
38.64% of assets| Name | Symbol | Weight |
|---|---|---|
| Natera, Inc. | NTRA | 5.36% |
| Bruker Corporation | BRKR | 4.28% |
| Halozyme Therapeutics, Inc. | HALO | 3.85% |
| Mettler-Toledo International Inc. | MTD | 3.74% |
| Waters Corporation | WAT | 3.70% |
| Exact Sciences Corporation | EXAS | 3.67% |
| United Therapeutics Corporation | UTHR | 3.65% |
| Neurocrine Biosciences, Inc. | NBIX | 3.47% |
| Corcept Therapeutics Incorporated | CORT | 3.46% |
| Intra-Cellular Therapies, Inc. | ITCI | 3.46% |
News
Here are the top-performing ETFs in first half of 2023 as crypto-related funds soar
Hello! This week's ETF Wrap looks at top performers in the first half of 2023, as well as flows, as stocks rally and crypto-related funds jump so far this year.
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...
Biotech ETFs at multi-week highs, extending winning streak
Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...
Biotech ETFs at two-week highs on upbeat vaccine news
Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biote...
Election History Says Buy Biotech Dip
Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ign...
Post-Pandemic Stars Could Align For This Biotech ETF
These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.
Biotech stocks fall after Trump promises executive order drug prices
CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.